Frontier IP Group today announced that portfolio company Exscientia Limited ("Exscientia") has successfully completed its Series C funding round. Exscientia, is a clinical stage pharmatech company pioneering the use of artificial intelligence (AI) to design new drugs. Exscientia has today announced that funds managed by BlackRock joined the Company's Series C investment round. Including existing Series C investors, Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital, the roun ....
04 Mar 2021
VSA Morning Technology Comment (04/03/21)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
VSA Morning Technology Comment (04/03/21)
Frontier IP Group Plc (FIPP:LON) | 38.5 0 0.0% | Mkt Cap: 21.6m
- Published:
04 Mar 2021 -
Author:
Phil Smith -
Pages:
3
Frontier IP Group today announced that portfolio company Exscientia Limited ("Exscientia") has successfully completed its Series C funding round. Exscientia, is a clinical stage pharmatech company pioneering the use of artificial intelligence (AI) to design new drugs. Exscientia has today announced that funds managed by BlackRock joined the Company's Series C investment round. Including existing Series C investors, Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital, the roun ....